Hepatorenal Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Hepatorenal Syndrome Emerging Therapy and TPP Insights Thelansis’s “Hepatorenal Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Hepatorenal Syndrome Overview Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease, characterized by functional kidney failure in the absence of intrinsic renal pathology, most often occurring in patients with cirrhosis and portal hypertension, including those with alcoholic hepatitis or other causes of decompensated liver disease. It is precipitated by circulatory changes that lead to renal vasoconstriction, and common triggers include spontaneous bacterial peritonitis, gastrointestinal bleeding, and large‑volume paracentesis without plasma expansion, while seps...